Surgical PA-LAA Shunting: a Feasibility Study

LAA Thrombus Prevention Clinical Trial

— PA-LAA  

Official title:

Surgical PA-LAA Shunting for Management of Systemic Embolization in Patients With Atrial Fibrillation: a Feasibility Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04704791
• Other study ID #: 20200646-01H
• Status: Withdrawn
• Phase: N/A
• Start date: March 19, 2021
• Est. completion date: December 15, 2021

Study information

• Verified date: October 2022
• Source: Ottawa Heart Institute Research Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Atrial fibrillation is common and increases the risk of stroke. Traditionally patients are treated with blood thinning medications or at the time of surgery the part of the heart where blood clots form is cut out. Surgically cutting out the left atrial appendage can be difficult and complications can occur. An alternative strategy is to create a tunnel to increase blood flow and wash out the part of the heart where clots form. This strategy has not been previously studied. The purpose of this study is to determine if creating a tunnel to increase blood flow is feasible and safe.

Description:

The goal is to understand the potential avenues to increase Left Atrial Appendage (LAA) flow in patients with Atrial Fibrillation (AF) to minimize systemic embolization risk. Flow modeling demonstrates that the anatomy of the LAA results in decreased velocities in the LAA apex. Introduction of a 3-4mm shunt in the apex can result in increased velocity, less stasis and a lower propensity for thrombus formation. Small (<8mm) inter-chamber shunts can exist in humans with no long term hemodynamic consequences in otherwise structurally normal hearts - making a strategy of pulmonary artery (PA) to LAA shunt an attractive potential therapy given anatomic proximity and gradient differential between the cardiac chambers. This will be a 5 patient first-in-human feasibility study. The population will include patients undergoing CABG or other cardiovascular surgery with AF and a CHADS2 score >1 in whom the treating team deems traditional therapy with anticoagulants is prohibitive or ineffective (dialysis or EGFR preoperatively <15, previous bleeding with non-reversible pathology, clinically deemed contraindicated to oral anticoagulant). The intervention will be PA-LAA shunt creation at the time of surgery. As this is a single arm study there will be no comparison group.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 15, 2021
• Est. primary completion date: December 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years undergoing CV surgery
• History of AF with a CHADS2 score >1
• Relative contraindication to OAC as determined by the heart team

1. Dialysis or preoperative eGFR of <15

2. Bleeding on DOAC/Coumadin with non-reversible pathology

3. Other medical condition that makes the patient ineligible for OAC

• Anatomic proximity of LAA and PA on preoperative CT scan suitable for shunt creation

Exclusion Criteria:

• LVEF <40%
• History of VTE - either DVT or PE
• Resting baseline preoperative O2 sats <98%
• Inability of the patient to provide written informed consent
• Greater than moderate valvular heart disease which is not to be addressed during surgical intervention
• Documented mPA to PCWP <5mmHg

Related Conditions & MeSH terms

• LAA Thrombus Prevention
• Thrombosis

Intervention

Procedure:
• PA-LAA shunt
At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.

Locations

Country	Name	City	State
Canada	University of Ottawa Heart Institute	Ottawa	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Ottawa Heart Institute Research Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of device safety and performance	At three months feasibility will be met if there is no: Device related complications; Bleeding attributable to device implantation; Reintervention (surgical or percutaneous) on the shunt; Resting systemic saturations <92%; Documented Qp:Qs <0.8; Device related performance a. Shunt patency at 3 months as assessed by TEE	3 months
Secondary	Device related performance - maintaining patency	Shunt patency as assessed by TEE	1 year
Secondary	Systemic embolization	Systemic embolization - includes stroke, TIA, MI or peripheral embolization attributable to either LAA thrombus or paradoxical embolization as clinically diagnosed by treating physician	1 year
Secondary	Systemic saturations	Resting saturations <92% - threshold	1 year
Secondary	Need for intervention to close the shunt	Need for intervention to close the shunt either surgically or percutaneously to	1 year